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Abstract: 
Background and Aims: Multiple randomized controlled trials (RCT) using the second-generation 
distal attachment cuff device (Endocuff Vision) have reported conflicting results in improving 
adenoma detection rate (ADR) compared with standard high definition colonoscopy without distal 
attachment. We conducted a systematic review and meta-analysis of RCTs to compare outcomes 
between second-generation cuff colonoscopy (CC) versus colonoscopy without distal attachment 
(SC).  
Methods: An electronic literature search was performed using PubMed, Google Scholar, Embase, 
and Cochrane Library through May 2020. The primary outcome was reporting of ADR and 
secondary outcomes included polyp detection rate (PDR), mean withdrawal time, mean adenomas 
per colonoscopy (APC), sessile serrated lesion detection rate (SDR), and adverse events. Pooled 
rates and risk ratios with 95% confidence intervals were reported. 
Results: Eight RCTs with 5695 patients were included in final analysis. There were 2862 patients 
(mean age 62.8 years, 52.9% males) in CC group and 2833 patients (mean age 62.6 years, 54.2% 
males) in the SC group. Compared with SC, use of CC was associated with a significant improvement 
in ADR: 49.8% vs 45.6% (RR, 1.12; p=0.02); PDR, 58.1% vs 53% (RR, 1.12; p=0.009) and APC (p<0.01). 
Furthermore, use of CC had a 0.93 min lower mean withdrawal time (p < 0.01) when compared 
with SC. The difference in ADR was larger in the screening/surveillance population (6.5%; p= 0.02) 
and when used by endoscopists with ADR < 30% (9.4%; p= 0.03). 
Conclusion: The results of this meta-analysis of randomized trials show a significant improvement 
in ADR and APC with shorter withdrawal times using the second-generation cuff device compared 
with standard colonoscopy.   




Despite steadily decreasing trends in the incidence of colorectal cancer over the last 5 years, 
colorectal cancer still ranks second in the United States for cancer related mortality
1
. Colonoscopy, 
as a screening procedure, is a useful tool in detecting tumors at an earlier and more treatable stage 
and also facilitates the timely removal of precancerous lesions or adenomas
2
. Adenoma detection 
rate (ADR) has been proposed as a benchmark and a reportable colonoscopy quality measure by 
the Centers for Medicare and Medicaid Services
3–6
. ADR has been shown to be inversely associated 
with the risk of interval colorectal cancer
3,4
.  ADR can be improved by technique or devices that 
improve mucosal exposure, or by tools that highlight flat colonic lesions.  
A number of distal attachments have been tested to improve ADR including a transparent cap, cuff 
or rings. The cuff is attached to the tip of the colonoscope, and the fingers are used to flatten 
colonic folds and lead to increase mucosal visualization. Although a number of studies and analyses 
have been published, they had mostly used the first-generation cuff (Endocuff, UK) 
7–13
. More 
recently, a second-generation cuff (Endocuff Vision; Olympus America, Center Valley, Pa, USA) has 
been evaluated in several RCTs showing divergent results in improving ADR.  Compared with the 
first-generation device, the Endocuff Vision has only one row of flexible arms that are softer, 2 mm 
longer and available in 4 different sizes for different type of colonoscopes. The aim of this 
systematic review and meta-analysis was to compare the outcomes of cuff colonoscopy (CC) using 
the more recent and widely available second-generation device with standard high-definition 




This systematic review and meta-analysis along with the eligibility criteria and analyses were 
performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) Statement
14
 (Supplementary table 1). 
Search strategy: 
A comprehensive electronic literature search was conducted in PubMed/ MEDLINE, Google Scholar, 
EMBASE, Cochrane and major conference proceedings to identify eligible articles, from the 
beginning of indexing for each database through May 10, 2020. The following text words and 
Medical Subject Heading/ Entrée terms were for search: “Endocuff vision,” “Endocuff,” “distal 
attachment,” “adenoma detection rate,” “ADR,” “adenoma,” “polyp detection rate,” “PDR,” 
“screening,” “surveillance,” “withdrawal,” and “adverse events” (Supplementary table 2). 
Inclusion/ Exclusion criteria: 
The retrieved articles were screened for eligibility by 2 independent reviewers (H.P. and V.T.) and 
any disagreement was resolved by consensus with a third author (P.S.). The inclusion criteria for 
this analysis were (1) Studies reporting ADR using CC and SC, (2) prospective enrollment of patients 
undergoing colonoscopy, and (3) randomized study design.  Exclusion criteria were (1) studies not 
reporting ADR for either CC or SC in same study, (2) studies including patients with polyposis 
syndrome and inflammatory bowel disease, (3) retrospective studies, prospective single-arm 
studies, case reports and case series, and (4) studies conducted using the first-generation cuff 
device. 
Data extraction and quality assessment: 
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The following data were extracted from each study in each group: study author, study design, age, 
gender, number of patients, ADR, total number of adenomas, polyp detection rate (PDR), sessile 
serrated lesion detection rate (SDR), advanced adenoma detection rate (A-ADR), proximal and 
distal ADR (P-ADR, D-ADR), cecal intubation rates (CIR), ileal intubation rate (IIR), mean adenomas 
per colonoscopy (APC), withdrawal times and adverse events.  
Definitions and outcomes: 
ADR was defined as the number of patients with at least one adenoma (tubular, villous or tubulo-
villous adenoma based on histopathology) divided by the total number of patients. PDR was 
defined as number of patients with at least one polyp divided by the total number of patients. SDR 
was defined as the number of patients with at least one sessile serrated lesion (sessile serrated or 
traditional serrated adenoma) divided by the total number of patients. A-ADR was defined as the 
total number of patients with at least one advanced adenoma (adenoma ≥ 10 mm in size, villous 
features or high-grade dysplasia). P-ADR was the number of patients with adenoma in the proximal 
colon (cecum, ascending colon, hepatic flexure, and transverse colon) divided by the total number 
of patients. D-ADR was the number of patients with adenoma in the distal colon (splenic flexure, 
descending colon, sigmoid colon, and rectum) divided by the total number of patients. APC was the 
number of adenomas detected in total divided by the number of patients who underwent 
colonoscopy. CIR was the proportion of patients who had a successful intubation of the cecum. 
Mean withdrawal time (MWT) was calculated by the time measured from reaching the cecum until 
examination of the colon was complete with withdrawing of the scope and termination of the 
procedure, excluding the time required for polypectomy. Serious adverse events recorded during 
5 
 
the procedure included the incidence of bleeding and perforation.  
 
The primary outcome of interest was comparing the ADR between the CC and SC groups. The 
secondary outcomes were as follows: PDR, SDR, A-ADR, P-ADR, D-ADR, APC, CIR, IIR, MWT and rate 
of adverse events. If there was moderate-high heterogeneity, subgroup and sensitivity analyses 
were performed as follows: (1) outcomes for screening and surveillance patients only; (2) outcomes 
for screening and surveillance patients after excluding the U.K. Bowel Cancer Screening Program 
(BCSP) FOBT positive patients (FOBT+); and (3) comparison of ADR between the 2 groups for studies 
reporting < 30%, <40%, <50% and > 50% ADR in the SC group (control arm). 
 
Statistical analyses  
The pooled proportions were calculated including the frequency of events over the total number of 
patients along with 95% confidence limits. Random-effects model described by DerSimonian and 
Laird was used for analysis. Risk ratios (RR) were calculated by comparison of the pooled 
proportions.  A P-value <0.05 was considered statistically significant. The corresponding forest plots 
were constructed with the weights of individual studies representing the size of individual squares. 





of 0% to 30%, 31% to 60%, 61% to 75% and 76% to 100% were reflective of low, moderate, 
substantial, and considerable heterogeneity, respectively. Comparison of APC and withdrawal times 
were performed by calculating the mean difference with standard error. Publication bias was 
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assessed by funnel plot and asymmetry was tested using the Rucker test. The number of patients 
needed to be treated (NNT) for detecting one additional patient with an adenoma was calculated as 
the inverse of the difference of ADR between the 2 groups. All analyses were performed using 
statistical software, Open Meta analyst (CEBM, Brown University, Rhode Island, USA) and Review 
Manager version 5.3 (The Nordic Cochrane Center, Copenhagen, Denmark).  
Quality of evidence assessment 
The risk of bias in individual studies was assessed using the Cochrane Collaboration tool
15
. The 
quality of body of evidence was assessed using the Grading of Recommendations, Assessment and 
Evaluation (GRADE) approach
16
. Two independent researchers (H.P. and V.T.) graded risk of bias, 
indirectness, inconsistency, imprecision and publication bias and the quality was deemed high, 
moderate, low, or very low using GRADEPro (GRADEpro GDT: GRADEpro Guideline Development 
Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc). 
Results: 
A total of 469 articles were retrieved based on the initial search and after exclusions, 21 studies 
were reviewed in detail, of which 8 RCTs were included in the final analysis (Figure 1) 
12,13,17–22
. 
There were a total of 5695 patients: CC group (n=2862, 52.9% males, 62.8 +/- 2.9 years mean age) 
and SC group (n= 2833, 54.2% males, 62.6 +/- 3.4 years mean age). There was no difference in the 
proportion of males or mean age between the 2 groups. The indications for colonoscopy in most 
studies were varied (screening, surveillance and/or diagnostic) but 5 of the 8 studies
12,13,17,21,22
 
reported outcomes on screening and surveillance patients also. Of the 8 studies, 2 were from the 
United Kingdom (n= 2306)
12,13
, and one each from France (n=2058)
21







, Portugal (n= 170)
20
, Thailand (n= 404)
22
, and Australia (n= 320)
18
. Two studies 
were multicenter
13,17
 and 6 of them were single-center experiences
12,18–22
. Six studies were in full 
text format
12,13,17–19,21
 and 2 were abstracts
20,22
. Out of 4 studies that reported the information, 
endoscopists were experienced in all but one study (EVASTA)
19
 in using CC before initiation of trial. 
Detailed characteristics of each study with their demographics are reported in Table 1. Risk of bias 
assessment using Cochrane Collaboration tool is provided in Supplementary figure 1.  
Primary Outcome: ADR 
All 8 studies reported ADR in the CC and SC groups (n= 5695 patients) and it was reported as the 
primary outcome in 4 of 8 studies
13,18,21,22
 (Table 2, Figure 2, Supplementary Table 3). The Rucker’s 
coefficient for publication bias in these studies was p= 0.294, indicating no publication bias existed 
for primary outcome between the 8 studies (Supplementary Figure 2). The pooled ADR in the CC 
group was 49.8% (95% CI, 42.3 – 57.3%) and in the SC group was 45.6% (95% CI, 36.3% – 54.8%). 
The use of CC was associated with a statistically significant ~4.2% improvement in ADR when 
compared with SC (RR, 1.12; 95% CI, 1.02 – 1.23; p= 0.02; I
2
= 53%).   
If ADR calculation was restricted to the subgroup of patients undergoing either screening or 
surveillance colonoscopies
12,13,17,21,22
(n = 3294), the values were as follows: CC: 55.8% (95% CI, 
46.7% – 64.9%) and SC: 49.3% (95% CI, 37.7% – 61%) (RR, 1.15; 95% CI, 1.03 – 1.28; p= 0.02; I
2
= 
59%) (Figure 2; Supplementary Table 4). The NNT was calculated at 24 for all 8 studies and 15 if 
calculation was restricted to only screening/ surveillance studies. Further sensitivity analysis for the 





, yielded the following results: 51.7% vs 44.2% (RR, 1.21; 95% CI, 1.09 – 1.34; p= 
0.0004; I
2
= 3%; NNT 13), respectively for CC versus SC
17,21,22
 (Figure 2; Supplementary Table 5). 
Further subgroup analysis of ADR based on the baseline ADR of endoscopists involved in the RCTs 
yielded the following results (Supplementary Figure 3; Supplementary Table 5).  For operators with 
low baseline ADR< 30%, ie, the low detectors (n= 2378)
18,21
: 38.8% vs 29.4% (RR, 1.32; 95% CI, 1.18 
– 1.48; p< 0.01; I
2
= 0%); baseline ADR< 40% (n= 4150)
13,18,21
: 39.7% vs 31.9% (RR, 1.23; 95% CI, 1.09 
– 1.39; p= 0.0009; I
2
= 45%); baseline ADR< 50% (n= 4390)
13,18,19,21,22
: 41.4% vs 36.7% (RR,1.16; 95% 
CI, 1.03 – 1.31; p= 0.01; I
2
= 51%); and baseline ADR> 50%, ie, the very high detectors (n= 901)
12,17,20
: 
64% vs 60.8% (RR, 1.03; 95% CI, 0.93 – 1.14; p= 0.51; I
2
= 0%). Thus, ADR improved in the CC group 
for detectors up to 50% but no difference was seen beyond that. The NNT further decreased to 11 
for baseline ADR< 30%.  
Restricting the analysis further to include only the 3 studies which reported withdrawal time
13,17,21
, 
the ADR was higher with CC vs SC: 41% vs 33.5% (RR, 1.21; 95% CI, 1.08 – 1.36; p= 0.001; I
2
= 0%), 
respectively (NNT 13). If the population was limited to screening/surveillance subgroup in those 3 
studies, the difference in ADR was further higher with CC vs SC: 50.9% vs 40.9% (RR, 1.24; 95% CI, 
1.14 – 1.35; p<0.0001; I
2
= 0%), respectively (NNT 10) (Supplementary Figure 4, Supplementary 
Table 5).  
Secondary Outcomes: 
Sessile Serrated Lesion Detection Rate (SDR): Five studies reported the SDR (n= 4520)
13,17,18,20,21
 
(Table 2, Figure 3, Supplementary Table 3). The CC and SC groups had individual pooled rates of 
8.8% (95% CI, 3.1%– 14.4%) and 6.1% (95% CI, 0.7 – 11.5%), respectively, with no statistically 
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significant difference in the SDR (RR, 1.21; 95% CI, 0.90 – 1.61; p= 0.20; I
2
 = 18%). If analysis was 
restricted to the screening/surveillance population only (n= 2299)
13,17,21
, the SDR was significantly 
higher in the CC group: 12.1% vs 8.3% (RR, 1.28; 95% CI, 1.01 – 1.64; p= 0.04; I
2
 = 0%) for CC and SC, 
respectively (Supplementary table 4).  
Mean Adenomas per Colonoscopy (APC): Seven studies reported the APC in the CC group and SC 
group (Supplementary Table 3): 1.18 +/- 0.33 (n= 2680 patients) and 1.05 +/- 0.36 (n= 2695 
patients) respectively
12,13,17,19–22
. The mean difference between the 2 groups was statistically 
significantly higher for the CC group detecting 0.13 more adenomas compared with SC group 
(Standard error, 0.009; 95% CI, 0.11 - 0.15; p < 0.0001).  
Advanced Adenoma Detection Rate (AADR): Advanced adenoma detection rate was reported in 
only 3 of the 8 studies (n= 4361)
12,13,21
 (Table 2, Figure 3, Supplementary Table 3). The use of CC 
did not show any statistically significant increase in AADR when compared with the SC group: 11.4% 
(95% CI, 7.5 – 15.4%) vs 10.8% (95% CI, 6.5 – 15.2%), respectively; (RR, 1.11; 95% CI, 0.93 – 1.33; p= 
0.499, I
2
 = 0%).  
Proximal and Distal Adenoma Detection Rate (P-ADR and D-ADR): The P-ADR and the D-ADR were 
reported by 3 of 8 studies
13,18,21
. The use of CC did not improve the P-ADR but improved D-ADR 
compared with SC (Table 2, Figure 3, Supplementary Table 3): 29.9% (95% CI, 20.1% -39.7%) vs 
25.5% (95% CI, 21.9% – 29%) (RR, 1.26; 95% CI, 0.94 – 1.68; p =0.12; I
2
 = 81%) for P-ADR and 25.2% 
(95% CI, 23.2% – 27.3%) vs 18.2% (95% CI, 13.7% – 22.8%) (RR, 1.31; 95% CI, 1.09 – 1.58; p= 0.004; 
I
2 
= 41%) for D-ADR respectively. In the screening/surveillance population from 2 studies (n= 
2099)
13,21
, again there was no difference in P-ADR between the CC and SC groups (Supplementary 
10 
 
Table 4): 39.9% (95% CI, 36.9% - 42.8%) vs 29.7% (95% CI, 20.7% – 38.6%); (RR, 1.24; 95% CI, 0.96 – 
1.58; p= 0.09) but CC resulted in detection of more distal adenomas than SC: 32.1% (95% CI, 16.8% - 
47.3%) vs 25.6% (95% CI, 10.3% – 40.9%) respectively; (RR, 1.26; 95% CI, 1.10 – 1.45; p< 0.01). 
Polyp Detection Rate (PDR): Five studies reported the PDR (n = 4921)
12,13,18,19,21
(Table 2, Figure 3, 
Supplementary Table 3). The PDR for CC was significantly higher than SC: 55.5% (95% CI, 47.4% – 
63.6%) vs 49.8% (95% CI, 38.8% – 60.8%) (RR, 1.13; 95% CI, 1.03 – 1.23; p= 0.009; I
2
 = 54%), 
respectively. When the analysis was restricted to only screening/surveillance population (n = 
2630)
12,21
, the difference was still significant and greater (Supplementary table 4): 62% (95% CI, 
42% – 82%) vs 53.2% (95% CI, 30.7% – 75.7%) (RR, 1.14; 95% CI, 1.07 – 1.21; p<0.01), respectively.  
Mean Withdrawal Time and other outcomes: The MWT was reported by 3 studies
13,17,21
 and was 
significantly lower in the CC group (7.19 ± 0.62 minutes; 2015 patients) compared with the SC group 
(8.12 ± 0.30 minutes; 2015 patients) with a significant mean difference of 0.93 minute (SE, 0.02; 
95% CI, 0.89 - 0.97; p < 0.0001) (Table 2).  For additional secondary outcomes including the CIR, IIR 
and Adverse Events there was no significant difference between the 2 groups. Table 2 reports for 
individual pooled rates and RR for all the detection endpoints.  
Quality assessment by GRADE estimate: 
The quality of evidence based on GRADE approach was found to be moderate for ADR for screening 
and surveillance population and low for ADR, PDR, SDR, A-ADR, APC, and MWT. (Table 2, 
Supplementary table 6). The level of evidence was downgraded by 2 levels primarily due to the 
following reasons: concerns for risk of bias as the endoscopists were not blinded to the study 
groups or outcomes and also due to the presence of indirectness due to different study populations 
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and indications for procedure. Overall, the quality of evidence based on the estimates was 
considered low. 
Discussion:  
This systematic review and meta-analysis of RCTs reports quality measure outcomes in patients 
undergoing colonoscopy using either a distal cuff attachment versus no attachment.  The results 
including 8 RCTs
12,13,17–22
 demonstrate a 4.2% increase in ADR (RR, 1.12; p= 0.02), a 5.1% increase in 
PDR (RR, 1.13; p= 0.009), a 0.13 increase in APC along with an approximate 1 minute shorter 
withdrawal time when the second generation cuff device was used compared with a standard 
colonoscopy without any distal attachment. The distal ADR was also significantly higher in the CC 
group by 7% (25.2% versus 18.2%), but there was no significant difference in the serrated lesion 
ADR, cecal intubation rates or the proximal ADR between the 2 groups. Prior meta-analyses have 
been published on the utility of distal attachment devices such as cap, and cuff; however, the cuff 
results were based primarily on the first-generation tip device.  
The E-CAP study by Bhattacharya et al
12
 was the first randomized study comparing CC and SC where 
all patients enrolled in the study were FOBT+ from the National BCSP in the United Kingdom. 
Contrary to the results of this meta-analysis, there was no significant difference in endpoints (ADR, 
APC, and PDR) between both of the groups from this study. One possible explanation could be the 
high baseline ADR of endoscopists (58.5%) in the United Kingdom study and higher ADR in FOBT+ 
patients compared with other populations
23
, making it difficult to improve ADR further with the use 
of any distal attachment device. However, Karsenti et al
21
 reported that the ADR with CC 
significantly improved in the high-detector group. However, the cut-off for high ADR in their study 
12 
 
was >/=25%, which overlaps with the low-detector group in prior meta-analyses and prior RCTs.  
Consequently, high-ADR endoscopists will probably not benefit from the use of CC or any other 
attachment device; this was shown in our current analysis based on baseline ADR. Stratifying 
studies into groups based on ADR from the SC arm (control arm) as <30%, <40%, <50% and ≥50%, 
we showed that operators with baseline ADR < 30%
18,21
 benefit from the use of CC (NNT 11), 
whereas the very high baseline detectors (ADR> 50%)
12,17,20




 in their study highlighted the significance of withdrawal times. As reported in prior 
studies, they suggested that CC helps reduce procedural times and technical success without 
compromising the endpoints for outcomes
24,25
. However, that study was not adequately powered 





 which constituted the majority of the patients. Ngu et al,
13
 with a large sample size of 
1772 patients, reported improved ADR, PDR, SDR, D-ADR, and APC but no difference in mean 
withdrawal time using CC (Supplementary Table 3). Karsenti et al,
21
 in a large cluster randomized 
cross over trial (n= 2058) reported close to a 10% improvement in ADR and significantly lower 
withdrawal times using CC. Given the differences in the above studies, our meta-analysis reports 
important results of improvement in ADR, and APC while reducing the mean withdrawal time in the 
CC compared with SC group.  
In order to minimize the influence of the outcomes from non-screening or non-surveillance 
procedures, we performed a subgroup analysis based on indications for colonoscopy including 
patients undergoing a screening or surveillance colonoscopy (n = 3234)
12,13,17,21,22
. There was a 
13 
 






. The NNT based on 
the ADR for this subgroup was 15. An interesting observation was the significant increase in the SDR 
in this subgroup with the use of CC over SC: 12.1% vs 8.3% (RR, 1.28; p= 0.04). However, there was 
still a high heterogeneity in this subgroup for the primary outcome ADR (I
2
= 59%). Thus, we 
performed a further sensitivity analysis by excluding 2 studies that included FOBT+ population and 
found persistent improvement in the ADR with minimal heterogeneity (I
2
= 3%) further reducing the 
NNT to 13.  
Finally, our results show that an attachment with flexible arms at the tip of the endoscope did not 
translate into increased adverse events. Prior meta-analysis with the first-generation cuff compared 
with SC by Chin et al have shown more adverse events and specifically mucosal abrasions when 
compared with SC
26
. On the contrary, studies with the second-generation device have not shown 
similar results and our meta-analysis reaffirms these results.  
The strength of the current analysis lies in the inclusion of only RCTs with more than 5500 patients.  
This meta-analysis specifically focuses on all outcomes for only second-generation cuff device 
compared with screening colonoscopy which have not been reported before. The majority of 
outcomes reported in our study had only mild or moderate heterogeneity. The potential reasons 
for heterogeneity include studies being performed in different countries with different patient 
populations, varying expertise and experience of endoscopists, variations in bowel preparation and 
withdrawal time. In case of moderate to high heterogeneity, we have performed further subgroup 
and sensitivity analyses to successfully identify and reduce or eliminate the heterogeneity for most 
outcomes.  However, there are limitations to the study. The endoscopists in both groups were not 
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blinded, which is common to most endoscopic studies designed for assessment of external 
attachments. Data on polyp size, adenoma miss rate and cancer outcomes were limited because 
there were no follow-up data in these studies, and we could not perform an analysis for these 
outcomes. There were different scales used for grading the quality of bowel preparation across 
different studies, making it difficult to generalize the outcomes, but individual studies did not have 
significant difference in bowel preparation between both the groups, thus the results from our 
analysis holds good, even if we were unable to analyse outcomes based on the bowel preparation. 




In conclusion, the use of the second-generation cuff distal attachment device was associated with a 
significant improvement in adenoma detection rate, adenomas per colonoscopy, a reduction in the 
mean withdrawal time without any increase in adverse events compared with standard high-
definition colonoscopy without any distal attachment. The benefit in ADR was more pronounced in 
patients undergoing screening and/or surveillance colonoscopy and for endoscopists with baseline 
low ADR. Future studies with stratification of outcomes based on polyp size and evaluation of cost-
effectiveness are needed. 
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Table 1. Study Characteristics with demographics and indications: 
 
CC: Cuff Colonoscopy; SC: Standard Colonoscopy; ADR: Adenoma Detection Rate; EV: Endocuff 
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68; 67 60.9; 
67.9 
MPP 100;  
100 (FOBT+) 
NA 





































 NA 56.7; 
59.3 
ADR NA 4 
Procedures 











































































ADR: Adenoma Detection Rate; PDR: Polyp Detection Rate; SDR: Sessile Serrated Lesion Detection 
Rate; AADR: Advanced ADR; P-ADR: Proximal ADR; D-ADR: Distal ADR; CDR: Cancer Detection Rate; 













CC % (95% CI) SC % (95% CI) Risk Ratio (95% CI; P value; I
2
) Quality of 
Evidence per 
GRADE 
ADR (8) 49.8 (42.3 – 57.3) 45.6 (36.3 – 54.8) 1.12 (1.02 – 1.23; 0.02; 53%) Low 
PDR (5) 58.1 (49 .5 – 
66.8) 
53 (40.7 – 65.4) 1.13 (1.03 – 1.23, 0.009, 54%) Low 
SDR (5) 8.8 (3.1 – 14.4) 6.1 (0.7 – 11.5) 1.21 (0.90 – 1.61; 0.20; 18%) Low 
AADR (3) 11.4 (7.5 – 15.4) 10.8 (6.5 – 15.2) 1.11 (0.93 – 1.33; 0.49, 0%) Low 
P-ADR (3) 29.9 (20.1 -39.7) 25.5 (21.9 – 29) 1.26 (0.94 – 1.68; 0.12; 81%) NA 
D-ADR (3) 25.2 (23.2 – 27.3) 18.2 (13.7 – 22.8) 1.31 (1.09 – 1.58; 0.004; 41%) NA 
IIR (3) 50 (21.9 - 78.1)  58.7 (22.6 - 94.8) 0.83 (0.68 – 1.02; 0.07; 81%) NA 
CIR (7) 97.8 (96.4 – 99.2) 98.7 (97.7 – 99.7) 0.99 (0.98 – 1.01; 0.46; 68%) NA 
Adverse Events 
(7) 




Figure 1: PRISMA Flowchart of study selection process 
Figure 2: Comparison of ADR between Cuff assisted Colonoscopy and Standard Colonoscopy in form 
of Risk Ratio Forest Plot. A, All 7 RCTs. B, 5 RCTs Reporting Screening/Surveillance Population. C, 
Exclusion FOBT+ population from the screening/surveillance subgroup 
Figure 3: Comparison of outcomes between Cuff-assisted Colonoscopy and Standard Colonoscopy 
in form of Risk Ratio Forest Plot. A, PDR. B, SDR. C, P-ADR. D, D-ADR.  
Figure 4: Graphical comparison of ADR between Cuff-assisted colonoscopy and Standard 























List of Abbreviations- 
ADR – Adenoma Detection Rate 
APC – Mean Adenomas Per Colonoscopy 
A-ADR – Advanced Adenoma Detection Rate 
CC – Cuff Colonoscopy 
CIR – Cecal Intubation Rate 
D-ADR – Distal Adenoma Detection Rate 
EV – Endocuff Vision 
IIR – Ileal Intubation Rate 
MWT – Mean Withdrawal Time 
NNT – Number Needed to Treat 
PDR – Polyp Detection Rate 
P-ADR – Proximal Adenoma Detection Rate 
RCT - Randomized Controlled Trial 
RR – Risk Ratio 
SC – Standard Colonoscopy 
SDR – Sessile Serrated Lesion Detection Rate 
 
